A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

This study will consist of six treatment periods. A total of 16 healthy male and female participants of non-childbearing potential will be randomized in this study to ensure at least 12 evaluable participants at the end of the last treatment period. The study will comprise of a Screening Period, six Treatment Periods, and a follow-up phone call: * A screening period of maximum 28 days. * Six treatment periods during which participants will be residents at the study center from Day -1 until Day 17. Each participant will receive 6 treatments. The following treatments will be given:- * Treatment A: Dose A of AZD5462 film-coated tablet in a fasted state. * Treatment B: Dose A of AZD5462 film-coated tablet in a fed state. * Treatment C: Dose B of AZD5462 film-coated tablet in a fasted state. * Treatment D: Dose B of AZD5462 oral solution in a fasted state. * Treatment E: Dose C of AZD5462 film-coated tablet in a fasted state. * Treatment F: Dose C of AZD5462 film-coated tablet in a fed state. * A follow-up phone call will take place on Day 21 (± 1 day) to record adverse events (AEs) and concomitant medication.